Jun 01,2021

Medtronic Announces Scientific Data Presentations at the 14th International Conference on Advanced Technologies & Treatments for Diabetes

Data on the Company's Holistic Portfolio Will Include Real-World Data on MiniMed™ 780G System and New Data on Medtronic Continuous Glucose Monitoring Systems and Extended-Wear Infusion Set

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 02,2021

BD Advances Leadership in Cybersecurity Preparedness, Transparency

BD today announced that it has become the first medical technology company authorized as a Common Vulnerability and Exposures (CVE®) Numbering Authority by the CVE Program, further demonstrating the company's leadership in health care cybersecurity.

View Analyst & Ambassador Comments
Go to original news
Jun 02,2021

Real-World Data on Over 4,000 Patients Using the Medtronic MiniMed™ 780G System Demonstrate Time in Range Mirroring Pivotal Trial

Results Demonstrate 76% Time in Range and 94% Time in Advanced Hybrid Closed Loop Mode

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 04,2021

Tandem Diabetes Care Announces Presentations Demonstrating Immediate and Sustained Real-World Improvements with Control-IQ Technology

Tandem Diabetes Care, Inc. announced data presented this week on real-world use of the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed-loop technology at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD). Several presentations detailed positive outcomes, including a plenary session today by Boris Kovatchev, PhD, Director of the Center for Diabetes Technology at the University of Virginia, which demonstrated immediate and sustained improvements in time in range (TIR) in more than 9,000 people with diabetes who wore the system for 12 months.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 05,2021

Contactless temperature measurement and immediate printing with the Beurer FT 95 and the REINER jetStamp® 1025

Wherever people come together, the question currently arises as to how these meetings can be held in the future with as little risk as possible. A step towards a little more safety can be a new solution from the cooperation between the two traditional German companies Beurer and REINER ® . The combination of the contactless FT 95 clinical thermometer from Beurer and the handy inkjet printer jetStamp ® 1025 from REINER ® creates a mobile temperature measurement and documentation station. The body temperature can thus be determined in a matter of seconds and printed out directly. The devices could be used at events, trade fairs or at airports and could be useful tools, especially in the current pandemic situation.

View Analyst & Ambassador Comments
Go to original news
Jun 06,2021

Atos and Huma Enter Into Five-Year Partnership to Improve Healthcare and Research With Innovative Remote Monitoring Technologies

Atos and Huma have announced a 5-year strategic global partnership to shift healthcare and clinical trials from hospital to home. The partnership will focus on Huma’s modular platform which can power digital ‘hospitals at home’ up to national scale, as well as support pharmaceutical and research industries to run complex global decentralized clinical trials. The platform is already used in the US and across Europe for illnesses ranging from atrial fibrillation to diabetes to Covid-19. Atos will use its experience in implementing and scaling complex transformation projects to accelerate adoption of Huma’s technology. This will include investment by Atos worth up to €20 million split across R&D and go-to-market resources, including dedicated consulting and sales personnel. The investment in R&D will fast-track the integration of the Huma platform with other leading clinical platforms, as well as develop a dedicated video module.

COLLABORATION PARTNERSHIP

#r&d

#rpm

View Analyst & Ambassador Comments
Go to original news
Jun 07,2021

Compatibility with New Insulins Opens Up New Market Opportunities for Brighter’s Actiste[®]

Brighter AB (publ) announced today that its solution for diabetes management – the Actiste®, has been evaluated and proved to be compatible with insulin cartridges from BIOTON S.A. (SciGen Pte. Ltd. – the exclusive distributor of BIOTON products, excluding Poland) with GENSULIN®GENSULIN® N (Scilin®N), GENSULIN® R (Scilin®R), and GENSULIN® M30(Scilin®M30). Currently, Actiste® is intended for use only with insulin cartridges from Sanofi. This has been a limiting factor to Brighter's potential market reach, because Sanofi cartridges are not available in all markets.

PRODUCT

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Jun 07,2021

Voluntis receives FDA 510(k) clearance for a new version of Insulia supporting an expanded range of basal insulins

Voluntis a leader in digital therapeutics, today announced that it has received the FDA 510(k) clearance for a new version of Insulia supporting an additional basal insulin product, expanding the scope of insulins covered by the solution. Voluntis’ flagship diabetes digital therapeutic, Insulia, helps people with type 2 diabetes with dose titration. It is indicated for patients with type 2 diabetes initiating or uncontrolled on basal insulin, treated with a wide range of basal insulin analogues, including all approved insulin glargines.

REGULATORY FDA

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 07,2021

An Examination of the Glucose Management Indicator in Young Children with Type 1 Diabetes

Previous studies utilizing glucose data from continuous glucose monitors (CGM) to estimate the Glucose Management Indicator (GMI) have not included young children or determined appropriate GMI formulas for young children with type 1 diabetes (T1D).

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 09,2021

Voluntis, a pioneer in digital therapies that has become a world leader, shows its ambitions for profitable growth

Voluntis, a leader in the field of digital therapies, today presents the results of its last years of development as well as its ambitions for the coming years.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES